Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome –positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study
To evaluate long-term durability of blinatumomab, a BiTE ® (bispecific T-cell engager) molecule, in adults with relapsed/refractory (R/R) Philadelphia chromosome–positive (Ph+) B-cell precursor acute lymphoblastic leukaemia (ALL).
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver Ottmann, Nicola G ökbuget, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Catherine A. Tuglus, Joan D. Morris, Anthony Stein Tags: Original Research Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Leukemia | Study